• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

New CPT code released for AMD treatment

Article

A new Category III CPT code was released by the American Medical Association Current Procedural Terminology (CPT) Editorial Panel.

Freemont, CA-A new Category III CPT code was released by the American Medical Association Current Procedural Terminology (CPT) Editorial Panel. The code for Neovista Inc.'s radiation therapy for the treatment of wet age-related macular generation (AMD) (0190T) will become effective July 1 and will be used with the code for performing a basic posterior vitrectomy (67036).

"We at NeoVista believe that our unique radiation therapy will eventually be shown to offer a less-time-consuming and less-costly alternative for physicians who treat patients with wet AMD," said John Hendrick, president and chief executive officer of NeoVista. "Obtaining a Category III CPT code is a vital step towards our end-goal of seeing our therapy through to market launch, where it will be of help to millions of people suffering from wet AMD."

The code will eventually allow physicians to identify the novel epiretinal radiation treatment for wet AMD on insurance claims.

The American Academy of Ophthalmology and American Society of Therapeutic and Radiation Oncology supported Neovista through the code development.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.